newsfilter
← Latest News
GlobeNewswire·

I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update

Prioritization of givastomig as I-Mab's lead program positions the Company for clinical progressNew givastomig combination data selected for mini-oral presentation at ESMO GI, being held July 2-5 in Barcelona,